Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 1,800 shares of the stock in a transaction that occurred on Monday, July 17th. The stock was bought at an average price of $6.04 per share, with a total value of $10,872.00. Following the completion of the purchase, the chief executive officer now directly owns 3,068,951 shares in the company, valued at $18,536,464.04. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Friday, July 14th, Phillip Md Et Al Frost bought 12,600 shares of Opko Health stock. The stock was bought at an average price of $6.16 per share, with a total value of $77,616.00.
  • On Wednesday, July 12th, Phillip Md Et Al Frost bought 3,600 shares of Opko Health stock. The stock was bought at an average price of $6.12 per share, with a total value of $22,032.00.
  • On Monday, July 10th, Phillip Md Et Al Frost bought 50,000 shares of Opko Health stock. The stock was bought at an average price of $6.19 per share, with a total value of $309,500.00.
  • On Thursday, July 6th, Phillip Md Et Al Frost bought 25,000 shares of Opko Health stock. The stock was bought at an average price of $6.29 per share, with a total value of $157,250.00.
  • On Monday, July 3rd, Phillip Md Et Al Frost bought 60,800 shares of Opko Health stock. The stock was bought at an average price of $6.44 per share, with a total value of $391,552.00.
  • On Friday, June 30th, Phillip Md Et Al Frost purchased 3,600 shares of Opko Health stock. The shares were acquired at an average cost of $6.58 per share, with a total value of $23,688.00.
  • On Wednesday, June 28th, Phillip Md Et Al Frost purchased 1,800 shares of Opko Health stock. The shares were acquired at an average cost of $6.87 per share, with a total value of $12,366.00.
  • On Tuesday, June 27th, Phillip Md Et Al Frost purchased 21,800 shares of Opko Health stock. The shares were acquired at an average cost of $6.77 per share, with a total value of $147,586.00.
  • On Monday, June 26th, Phillip Md Et Al Frost purchased 1,800 shares of Opko Health stock. The shares were acquired at an average cost of $6.97 per share, with a total value of $12,546.00.
  • On Thursday, June 22nd, Phillip Md Et Al Frost purchased 131,000 shares of Opko Health stock. The shares were acquired at an average cost of $6.72 per share, with a total value of $880,320.00.

Opko Health, Inc. (OPK) remained flat at $6.05 during trading on Tuesday. The company had a trading volume of 671,877 shares. Opko Health, Inc. has a one year low of $5.99 and a one year high of $12.15. The firm’s 50 day moving average price is $6.59 and its 200-day moving average price is $8.10. The firm’s market cap is $3.38 billion.

Opko Health (NASDAQ:OPK) last posted its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by $0.02. The firm had revenue of $296.10 million during the quarter, compared to analyst estimates of $313.36 million. Opko Health had a negative net margin of 3.60% and a negative return on equity of 2.13%. Opko Health’s revenue was up 1.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.02) earnings per share. On average, analysts predict that Opko Health, Inc. will post ($0.20) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was originally published by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/07/18/insider-buying-opko-health-inc-opk-ceo-buys-1800-shares-of-stock.html.

Large investors have recently added to or reduced their stakes in the company. Eqis Capital Management Inc. boosted its stake in Opko Health by 16.5% in the second quarter. Eqis Capital Management Inc. now owns 39,781 shares of the biotechnology company’s stock valued at $262,000 after buying an additional 5,622 shares during the period. Creative Planning boosted its stake in Opko Health by 2.9% in the second quarter. Creative Planning now owns 164,388 shares of the biotechnology company’s stock valued at $1,082,000 after buying an additional 4,660 shares during the period. Fox Run Management L.L.C. bought a new stake in Opko Health during the second quarter valued at approximately $176,000. RK Asset Management LLC boosted its stake in Opko Health by 2.1% in the second quarter. RK Asset Management LLC now owns 906,731 shares of the biotechnology company’s stock valued at $5,966,000 after buying an additional 19,012 shares during the period. Finally, Piedmont Investment Advisors LLC boosted its stake in Opko Health by 173.7% in the first quarter. Piedmont Investment Advisors LLC now owns 160,825 shares of the biotechnology company’s stock valued at $1,287,000 after buying an additional 102,063 shares during the period. Institutional investors and hedge funds own 23.65% of the company’s stock.

A number of equities analysts have issued reports on OPK shares. Zacks Investment Research lowered shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Thursday, May 4th. Ladenburg Thalmann Financial Services reissued a “buy” rating and set a $19.50 price target on shares of Opko Health in a research report on Tuesday, June 6th. Jefferies Group LLC reissued a “hold” rating and set a $8.00 price target on shares of Opko Health in a research report on Monday, June 12th. Finally, BidaskClub raised shares of Opko Health from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the stock. Opko Health has an average rating of “Hold” and a consensus price target of $16.58.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.